a Department of Biomedical Engineering , University of Houston , Houston , TX , USA.
Expert Opin Drug Discov. 2018 Aug;13(8):765-777. doi: 10.1080/17460441.2018.1480718. Epub 2018 Jun 4.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a high risk of morbidity and mortality; however, there is no cure and the current medications are far from optimal in addressing efficacy and safety concerns. Over the past decade, various emerging technologies have been used in the search for novel drug targets of SLE which have resulted in numerous promising data. However, the systematic review and careful digestion of this information have been lacking. Areas covered: In this review, the authors summarize promising biomarkers and drug targets which have been identified via various multiplexing and high-throughput proteomic strategies. The authors also introduce emerging technologies which are hopeful to be used for the discovery of novel biomarkers and therapeutic targets of SLE in the near future. Expert opinion: Emerging proteomic technologies and genome-wide association studies (GWAS) have been the new driving forces in the discovery of novel biomarkers and promising therapeutic targets of SLE. Careful validation of these potential targets in lupus mouse models and clinical trials are urgently needed so that the next generation of target-specific medications can be developed for SLE patients.
系统性红斑狼疮（SLE）是一种复杂的自身免疫性疾病，发病率和死亡率都很高；然而，目前尚无治愈方法，而且现有的药物在解决疗效和安全性问题方面远非理想。在过去的十年中，各种新兴技术已被用于寻找 SLE 的新型药物靶点，这带来了许多有希望的数据。然而，对这些信息的系统评价和仔细消化却一直缺乏。涵盖领域：在这篇综述中，作者总结了通过各种多重和高通量蛋白质组学策略确定的有前途的生物标志物和药物靶点。作者还介绍了一些新兴技术，这些技术有望在不久的将来用于发现 SLE 的新型生物标志物和治疗靶点。专家意见：新兴的蛋白质组学技术和全基因组关联研究（GWAS）是发现 SLE 新型生物标志物和有希望的治疗靶点的新动力。迫切需要在狼疮小鼠模型和临床试验中仔细验证这些潜在靶点，以便为 SLE 患者开发下一代靶向药物。
